Neurocrine Biosciences (NBIX) ROE US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | 5 years average | |||
| ROE, % | ? | 6.52% | 9.05% | 11.2% | 13.2% | 14.7% | 19.6% | ||
| Changes by years, y/y, % | -30pp | +3pp | +2pp | +2pp | +2pp | 11% | |||
Neurocrine Biosciences. ROE, %
Neurocrine Biosciences. ROE, changes, pp
Neurocrine Biosciences (NBIX) ROE US GAAP (quarter values) |
||||||||
| FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | FY2026Q2 | LTM ? | |||
| ROE, % | ? | 14.2% | 14.7% | 19.6% | 17.7% | 19.1% | 19.6% | |
| Changes by years, y/y, % | +0pp | +2pp | +8pp | +5pp | +6pp | |||
| Changes by quarters, q/q, % | +1pp | +0pp | +5pp | -2pp | +1pp | |||